Authors: Mansoor Raza Mirza, Elisabeth Avall-Lundqvist, Michael J. Birrer, et. al. Abstract: 5505 Clinical Trial Registry Number: NCT02354131 Citation: J Clin Oncol 37, 2019 (suppl; abstr 5505) Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum-based combination chemotherapy ± bevacizumab. However, this treatment modality is hardly curative, and is...
Pro zobrazení tohoto obsahu je třeba být přihlášen.